Cyclo Therapeutics Stock News

GAINESVILLE, Fla.--(BUSINESS WIRE)--Cyclo Therapeutics, Inc. (Nasdaq: CYTH) (“Cyclo Therapeutics” or the “Company”), a clinical stage biotechnology company dedicated to developing life-changin

GAINESVILLE, Fla.--(BUSINESS WIRE)--Cyclo Therapeutics, Inc. (Nasdaq: CYTH) (“Cyclo Therapeutics” or the “Company”), a clinical stage biotechnology company dedicated to developing life-changin

Anti-Amyloid Drugs: The Failure Of Success

Cyclo Therapeutics Inc - Class A (CYTH) shares closed 3.9% lower than its previous 52 week low, giving the company a market cap of $23M. The stock is currently down 15.6% year-to-date, down 28.2% over the past 12 months, and up 310.1% over the past five years. This week, the Dow Jones Industrial Average rose 3.9%, and the S&P 500 rose 4.9%. Trading Activity Trading volume this week was 42.1% lower than the 20-day average.Beta, a measure of the stocks volatility relative to the overall market stands at 1.3. Technical Indicators The Relative Strength Index (RSI) on the stock was under 30, indicating it may be underbought.MACD, a trend-following momentum indicator, indicates a downward trend.The stock closed below its Bollinger band, indicating it may be oversold. Market Comparative Performance The company's share price is the same as the S&P 500 Index , lags it on a 1-year basis, and beats it on a 5-year basis The company's share price is the same as the Dow Jones Industrial Average , lags it on a 1-year basis, and beats it on a 5-year basis Per Group Comparative Performance This story was produced by the Kwhen Automated News Generator. For more articles like this, please visit us at finance.kwhen.com. Write to [email protected]. © 2020 Kwhen Inc.

Cyclo Therapeutics, Inc. (OTCMKTS:CTDH) shares hit a new 52-week high on Wednesday . The stock traded as high as $4.11 and last traded at $4.00, with a volume of 31178 shares. The stock had previously closed at $4.09. The firm has a 50-day moving average of $5.74 and a two-hundred day moving average of $7.34. []

Cyclo Therapeutics, Inc. (NASDAQ:CYTH) was the recipient of a large decrease in short interest in the month of November. As of November 30th, there was short interest totalling 57,000 shares, a decrease of 36.0% from the November 15th total of 89,000 shares. Approximately 0.8% of the companys stock are short sold. Based on an average []

Cyclo Therapeutics, Inc. (NASDAQ:CYTH) CEO N Scott Fine acquired 5,000 shares of the businesss stock in a transaction on Wednesday, December 15th. The shares were bought at an average cost of $3.89 per share, for a total transaction of $19,450.00. The acquisition was disclosed in a legal filing with the SEC, which is available at []

GAINESVILLE, Fla.--(BUSINESS WIRE)--Cyclo Therapeutics, Inc. (Nasdaq: CYTH) (Cyclo Therapeutics or the Company), a clinical stage biotechnology company dedicated to developing life-changing medicines through science and innovation for patients and families living with diseases, today announced the appointment of Caroline Hastings, M.D. as Global Principal Investigator (PI) for its pivotal Phase 3 study (TransportNPC), which commenced in June 2021, evaluating Trappsol® Cyclo, the Compa

Cyclo Therapeutics (NASDAQ:CYTH) and Pledge Petroleum (OTCMKTS:PROP) are both medical companies, but which is the superior business? We will contrast the two companies based on the strength of their dividends, profitability, risk, valuation, institutional ownership, analyst recommendations and earnings. Analyst Ratings This is a summary of current recommendations and price targets for Cyclo Therapeutics and []

(RTTNews) - Cyclo Therapeutics, Inc. (CYTH) said on Monday that it has received necessary approval from the U.S. Food and Drug Administration or FDA for its initial investigational new drug or IND application to move ahead with the Phase 2 study of Trappsol Cyclo to treat early Alzheimer''s disease. "While our current focus continues to be on

GAINESVILLE, Fla.--(BUSINESS WIRE)--Cyclo Therapeutics, Inc. (Nasdaq: CYTH) (Cyclo Therapeutics or the Company), a clinical stage biotechnology company dedicated to developing life-changing medicines through science and innovation for patients and families living with diseases, today announced it has received notification that its study may proceed from the U.S. Food and Drug Administration (FDA) for its initial investigational new drug (IND) application for a Phase 2 study of Trappsol®

Shares of Cyclo Therapeutics, Inc. (OTCMKTS:CTDH) reached a new 52-week high during trading on Monday . The company traded as high as $5.48 and last traded at $5.47, with a volume of 101221 shares. The stock had previously closed at $5.28. The business has a fifty day moving average price of $6.44 and a 200 []

Geode Capital Management LLC increased its stake in Cyclo Therapeutics, Inc. (NASDAQ:CYTH) by 133.2% during the 2nd quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 42,577 shares of the companys stock after buying an additional 24,320 shares during the period. Geode Capital Management LLCs holdings in Cyclo []

Cyclo Therapeutics, Inc. (NASDAQ:CYTH) Director Francis Patrick Ostronic purchased 10,652 shares of Cyclo Therapeutics stock in a transaction that occurred on Friday, November 19th. The shares were bought at an average cost of $5.25 per share, with a total value of $55,923.00. The purchase was disclosed in a document filed with the Securities & Exchange []

Here's a roundup of top developments in the biotech space over the last 24 hours. Stocks In Focus Atea Announces Termination of Strategic Collaboration With Roche Atea Pharmaceuticals, Inc. (NASDAQ: A